Rankings
▼
Calendar
CTNM Q1 2023 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$504M
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$73,000
Operating Income
-$5M
Net Income
-$5M
EPS (Diluted)
$-0.19
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$494,000
Balance Sheet
Total Assets
$0
Total Liabilities
$0
Stockholders' Equity
$39M
Cash & Equivalents
-$47M
← FY 2023
All Quarters
Q2 2023 →
